Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.

Test time has arrived: the first person has been treated in a highly anticipated gene-therapy trial that aims to coax aged cells to take on a younger identity. The clinical trial is testing an ...

Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

A groundbreaking human trial of ER-100, a cellular reprogramming therapy, has begun, testing whether damaged eye cells can be rejuvenated and potentially opening a new chapter in the science of aging.

Today, more people are living past 100 than ever before — even though the maximum human lifespan hasn't moved past 115 years.

Could this work to prevent blindness and eventually turn back the clock in other organs too?

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. A first-of-its-kind shot that promises to reverse aging was just injected into a human body. It's a ...

Blindness itself might become, at least in certain cases, partially reversible. This potential future stems from one of the ...

A Boston biotech company has administered what researchers are describing as the first human dose of a cellular rejuvenation drug, a milestone in the effort to treat age-related disease at the ...

Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.

Life Biosciences says it just dosed its first patient in an FDA-approved clinical trial to reverse age-related blindness.